Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions

New research from prostate and bladder cancer Panoramic datasets offers pathways for optimized patient-centered care

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Flatiron Health announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers.

Why it matters

Recent advancements have fundamentally transformed treatment options for genitourinary cancers, but research reveals a critical gap: too many patients—particularly those with platinum-ineligibility, non-BRCA mutations, or comorbidities—are not benefiting from these breakthroughs. Flatiron's research aims to translate innovation into practice and guide clinicians in a rapidly evolving treatment landscape to enable personalized medicine.

The details

Flatiron's presence at ASCO GU 2026 is centered around the global prostate cancer and bladder cancer Panoramic datasets, which draw from over 420,000 relevant longitudinal patient records in Flatiron's network. These datasets enable researchers to seamlessly analyze patient outcomes and treatment patterns across markets to inform global evidence strategies. Research highlights include studies on the need for broader genetic testing and access to PARP inhibitors, the potential benefits of chemotherapy for selected cisplatin-ineligible bladder cancer patients, and the critical need for more effective therapy options following Lu177 treatment for metastatic castration-resistant prostate cancer.

  • The American Society of Genitourinary Cancers Symposium is happening from February 26-28, 2026, in San Francisco, California.

The players

Flatiron Health

A healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer.

Emily Castellanos, MD, MPH

Senior Medical Director and Head of Research Oncology at Flatiron Health.

Got photos? Submit your photos here. ›

What they’re saying

“Recent advancements have fundamentally transformed treatment options for genitourinary cancers, but our research reveals a critical gap: too many patients—particularly those with platinum-ineligibility, non- BRCA mutations, or comorbidities—are not benefiting from these breakthroughs.”

— Emily Castellanos, Senior Medical Director and Head of Research Oncology (Business Wire)

What’s next

Flatiron Health will be present at booth #26 during the ASCO GU 2026 Symposium, and the public can follow the company on X and LinkedIn for more updates from the event.

The takeaway

Flatiron Health's research at ASCO GU 2026 aims to translate advancements in genitourinary cancer treatments into more personalized and equitable care, addressing critical gaps in access and outcomes for patients with complex medical profiles or non-BRCA genetic mutations.